236 related articles for article (PubMed ID: 26051783)
1. Biological determinants of bladder cancer gene expression subtypes.
Aine M; Eriksson P; Liedberg F; Sjödahl G; Höglund M
Sci Rep; 2015 Jun; 5():10957. PubMed ID: 26051783
[TBL] [Abstract][Full Text] [Related]
2. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
[TBL] [Abstract][Full Text] [Related]
3. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
Sjödahl G; Eriksson P; Liedberg F; Höglund M
J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
[TBL] [Abstract][Full Text] [Related]
5. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
6. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.
Sjödahl G
Methods Mol Biol; 2018; 1655():53-64. PubMed ID: 28889377
[TBL] [Abstract][Full Text] [Related]
11. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
[TBL] [Abstract][Full Text] [Related]
12. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
[TBL] [Abstract][Full Text] [Related]
13. A molecular taxonomy for urothelial carcinoma.
Sjödahl G; Lauss M; Lövgren K; Chebil G; Gudjonsson S; Veerla S; Patschan O; Aine M; Fernö M; Ringnér M; Månsson W; Liedberg F; Lindgren D; Höglund M
Clin Cancer Res; 2012 Jun; 18(12):3377-86. PubMed ID: 22553347
[TBL] [Abstract][Full Text] [Related]
14. Bladder cancer outcome and subtype classification by gene expression.
Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
[TBL] [Abstract][Full Text] [Related]
15. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
[TBL] [Abstract][Full Text] [Related]
18. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
van der Kwast TH
Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.
Knowles MA; Hurst CD
Nat Rev Cancer; 2015 Jan; 15(1):25-41. PubMed ID: 25533674
[TBL] [Abstract][Full Text] [Related]
20. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ; Bryant D; Basu G; Bender R; Vranic S; Gatalica Z; Vogelzang NJ
Clin Genitourin Cancer; 2015 Feb; 13(1):e37-49. PubMed ID: 25178641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
